{"id":20497,"date":"2020-05-11T03:49:05","date_gmt":"2020-05-11T03:49:05","guid":{"rendered":"https:\/\/thepatientinvestor.com\/?p=20497"},"modified":"2020-05-13T06:18:49","modified_gmt":"2020-05-13T06:18:49","slug":"macquarie-group-ltd-mqg-2","status":"publish","type":"post","link":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/","title":{"rendered":"Macquarie Group Ltd (MQG)"},"content":{"rendered":"<table border=\"0\" summary=\"Current Price and Fair Value Estimate\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>Stock:<\/td>\n<td colspan=\"3\"><strong>Macquarie Group Ltd<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Exchange:<\/td>\n<td>ASX<\/td>\n<td>Symbol:<\/td>\n<td><strong>MQG<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Date:<\/td>\n<td>11-May-20<\/td>\n<td>Latest price:<\/td>\n<td><strong>$108.50<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Market Cap:<\/td>\n<td>$38.8 bn<\/td>\n<td>Fair Value:<\/td>\n<td><strong>$125.42<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Forward P\/E:<\/td>\n<td>15.6<\/td>\n<td>FV Payback (Years):<\/td>\n<td>11<\/td>\n<\/tr>\n<tr>\n<td>Forward Dividend Yield:<\/td>\n<td style=\"text-align: left;\">4.09%<\/td>\n<td>CET1 Capital Ratio:<\/td>\n<td>12.2%<\/td>\n<\/tr>\n<tr>\n<td>Financial Y\/E:<\/td>\n<td>31-Mar-21<\/td>\n<td>Rating:<\/td>\n<td><strong>HOLD<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Sector:<\/td>\n<td>Financial Services<\/td>\n<td>Industry:<\/td>\n<td>Capital Markets<\/td>\n<\/tr>\n<tr>\n<td>Investment Theme:<\/td>\n<td>Dividends &amp; Growth<\/td>\n<td>LT Trends:<\/td>\n<td>none<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Summary<\/h2>\n<p>We consider Macquarie (MQG) to be priced at below fair value, but the technical outlook is bearish.<\/p>\n<p>We rate the stock as a long-term <em>HOLD<\/em> because of its strong cash flows and competitive position. Weighting is 5.0% of portfolio value.<\/p>\n<h2>Valuation<\/h2>\n<p>We project flat annual revenue growth in the next 12 months, recovering to 8% in the long-term, with a provision of $1.5 billion to cover further impairment charges and under-performance of market-facing businesses. Estimated fair value is $125.42 with a payback period of 11 years.<\/p>\n<p>The payback period recognizes MQG&#8217;s strong market position but also the uncertainty of financial markets.<\/p>\n<h2>Technical Analysis<\/h2>\n<p>MQG is in a primary down-trend and we expect another test of primary support at 70 before the bear market is over. Trend Index and Momentum below zero both warn of bearish market sentiment. Respect of primary support would provide a solid base for a new primary up-trend. Breach is unlikely but would flag another decline and a strong bear market.<\/p>\n<p><img data-recalc-dims=\"1\" decoding=\"async\" class=\"aligncenter\" src=\"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg.png?w=525&#038;ssl=1\" alt=\"Twiggs Trend Index &amp; Twiggs Momentum (13-week)\" \/><\/p>\n<h2>Company Profile<\/h2>\n<p>Macquarie Group is Australia&#8217;s only sizable investment bank. Internationally diversified, the group employs 15,849 people in 31 countries, with its head office in Sydney, Australia.<\/p>\n<p>Macquarie was innovative in setting up large infrastructure funds which provided a captive client for the group but most of these were dissolved after the 2008 global financial crisis and have been replaced as an income source by other annuity businesses. FY20 net profit contribution by activity:<\/p>\n<p><img data-recalc-dims=\"1\" decoding=\"async\" class=\"aligncenter\" src=\"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg-segments.png?w=525&#038;ssl=1\" alt=\"MQG Profit Contribution by Division - FY20\" \/><\/p>\n<p><strong>Asset Management<\/strong> (MAM) manages infrastructure and real assets and securities investments for both retail and institutional clients in Australia and the US, with a total of $A607 billion under management in FY20.<\/p>\n<p><strong>Corporate and Asset Finance<\/strong> (CAF), with an asset and loan portfolio of $A21.3 billion (FY19) was broken up and integrated into MAM, CGM and Macquarie Capital in FY20.<\/p>\n<p><strong>Banking and Financial Services<\/strong> (BFS) has a retail deposit book of $63.9 billion, an Australian loan and lease portfolio of $A75.3 billion and a wealth management platform with funds of $A79.1 billion (FY20).<\/p>\n<p><strong>Commodities and Global Markets<\/strong> (CGM) offers broking, trading, hedging and finance on global securities markets including equities, fixed income, foreign exchange and commodities.<\/p>\n<p><strong>Macquarie Capital<\/strong> (MC) provides corporate finance advisory and capital raising services to corporate and government clients.<\/p>\n<h3>International Income<\/h3>\n<p><img data-recalc-dims=\"1\" decoding=\"async\" class=\"aligncenter\" src=\"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg-geog.png?w=525&#038;ssl=1\" alt=\"MQG International Income - FY20\" \/><\/p>\n<p><em>International income<sup>1<\/sup> is net operating income excluding earnings on capital. Australia<sup>2<\/sup> includes New Zealand.<\/em><\/p>\n<h3>Competitors<\/h3>\n<p>Macquarie competes with local commercial banks, fund managers and securities houses, and \u2014 with 67% international income in FY20 \u2014 a multitude of international investment banks.<\/p>\n<h2>Performance<\/h2>\n<p>Annuity-based businesses performed well in FY20 but cyclical, market-facing divisions experienced a significant fall in net profit contribution.<\/p>\n<h3>Asset Growth<\/h3>\n<ul>\n<li>MAM assets under management grew 10% to $605.7bn in FY20, compared to $551bn in FY19;<\/li>\n<li>Banking &amp; Financial Services (BFS) loans and leases grew 20% to $75.3 bn, funded by a 20% increase in deposits to $63.9 bn.<\/li>\n<\/ul>\n<h3>Segments<\/h3>\n<p>Market-facing businesses under-performed in terms of net profit contribution<sup>1<\/sup> in FY20:<\/p>\n<ul>\n<li>Commodities and Global Markets (CGM) were level with FY19; while<\/li>\n<li>Macquarie Capital (MC) fell 75% after a stellar 89% increase in FY19.<\/li>\n<\/ul>\n<p>Annuity-style businesses improved in FY20:<\/p>\n<ul>\n<li>Asset Management (MAM) was up 16%;<\/li>\n<li>Banking &amp; Financial Services (BFS) were up 2%.<\/li>\n<\/ul>\n<p><em>Net Profit Contribution<sup>1<\/sup> is calculated before unallocated corporate costs, profit share and income tax.<\/em><\/p>\n<h3>Return on Equity<\/h3>\n<p>Return on equity fell to 13.6% due to an 88% increase in impairment charges ($1.04 bn compared to $552 m in FY19), related to the COVID19 outbreak and weak results from market-facing businesses.<\/p>\n<p><img data-recalc-dims=\"1\" decoding=\"async\" class=\"aligncenter\" src=\"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg-roe.png?w=525&#038;ssl=1\" alt=\"MQG Return on Equity and Return on Assets\" \/><\/p>\n<h3>Margins<\/h3>\n<p>Staff costs are Macquarie&#8217;s largest operating expense. Long-term growth in the ratio of Net Income to Employment Costs reflects Macquarie&#8217;s increased ability to leverage operating expenses.<\/p>\n<p><img data-recalc-dims=\"1\" decoding=\"async\" class=\"aligncenter\" src=\"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg-staff.png?w=525&#038;ssl=1\" alt=\"MQG Net Income\/Total Compensation\" \/><\/p>\n<h3>Assets under management<\/h3>\n<p>Assets under management have grown at a compound annual rate of 6.4% over the last 10 years (FY10 to FY20).<\/p>\n<h3>Earnings per share<\/h3>\n<p>Earnings per share (EPS) has grown at a compound annual rate of 8.6% over the last 10 years or 9.6% over the last 5 years.<\/p>\n<p><img data-recalc-dims=\"1\" decoding=\"async\" class=\"aligncenter\" src=\"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg-eps.png?w=525&#038;ssl=1\" alt=\"MQG EPS\" \/><\/p>\n<p>We project long-term growth of 8% in annuity-based assets (AM, BFS &amp; CAF) and in earnings per share.<\/p>\n<h3>Capital structure<\/h3>\n<p>CET1 (Common Equity Tier 1) Capital Ratio improved to 12.2% in FY20 (FY19: 11.4%) calculated on risk-weighted assets using APRA Basel III standards.<\/p>\n<p>The unweighted CET1 Leverage Ratio, based on total credit exposure, however, weakened to 5.1% in FY20 .<\/p>\n<p>Capital ratios are adequate but not strong by our standards.<\/p>\n<h4>Dividends<\/h4>\n<p>Dividend payout of $4.30 (40% franked) for FY20 is down 25% compared to FY19 ($5.75 and 45% franked). We consider the dividend payout ratio of 56% (FY20) to be sustainable.<\/p>\n<h2>Forward guidance<\/h2>\n<p>Guidance for FY21 has been withheld because of uncertainty surrounding the COVID19 outbreak.<\/p>\n<p>We have made a provision of $1.5 billion to allow for uncertainty over further impairment charges and under-performance of market-facing businesses.<\/p>\n<h2>Strengths &amp; weaknesses<\/h2>\n<p>Macquarie is a world-leading infrastructure fund manager and in an excellent position to capitalize on massive expected investment in global infrastructure and renewable energy over the next decade.<\/p>\n<h3>Weaknesses<\/h3>\n<p>Like most investment banks, Macquarie relies on market knowledge and resourcefulness to identify new opportunities and innovate existing businesses. While they have an excellent track record, they can still make mistakes.<\/p>\n<p>Cyclical fluctuations may affect performance.<\/p>\n<p>BFS exposure to the highly-priced Australian property market is a vulnerability.<\/p>\n<h4>Disclosure<\/h4>\n<p>Staff of The Patient Investor may directly or indirectly own shares in the above company.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Stock: Macquarie Group Ltd Exchange: ASX Symbol: MQG Date: 11-May-20 Latest price: $108.50 Market Cap: $38.8 bn Fair Value: $125.42 Forward P\/E: 15.6 FV Payback (Years): 11 Forward Dividend Yield: 4.09% CET1 Capital Ratio: 12.2% Financial Y\/E: 31-Mar-21 Rating: HOLD Sector: Financial Services Industry: Capital Markets Investment Theme: Dividends &amp; Growth LT Trends: none Summary &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Macquarie Group Ltd (MQG)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3799],"tags":[3854,3838],"class_list":["post-20497","post","type-post","status-publish","format-standard","hentry","category-asx-growth","tag-macquarie-group","tag-mqg"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Macquarie Group Ltd (MQG) - the patient investor<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Macquarie Group Ltd (MQG) - the patient investor\" \/>\n<meta property=\"og:description\" content=\"Stock: Macquarie Group Ltd Exchange: ASX Symbol: MQG Date: 11-May-20 Latest price: $108.50 Market Cap: $38.8 bn Fair Value: $125.42 Forward P\/E: 15.6 FV Payback (Years): 11 Forward Dividend Yield: 4.09% CET1 Capital Ratio: 12.2% Financial Y\/E: 31-Mar-21 Rating: HOLD Sector: Financial Services Industry: Capital Markets Investment Theme: Dividends &amp; Growth LT Trends: none Summary &hellip; Continue reading &quot;Macquarie Group Ltd (MQG)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/\" \/>\n<meta property=\"og:site_name\" content=\"the patient investor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61572934660810\" \/>\n<meta property=\"article:author\" content=\"https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-11T03:49:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-05-13T06:18:49+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/static.incrediblecharts.com\/images\/2020\/2020-05-11-mqg.png\" \/>\n<meta name=\"author\" content=\"Colin Twiggs\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Colin Twiggs\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/\"},\"author\":{\"name\":\"Colin Twiggs\",\"@id\":\"https:\/\/thepatientinvestor.com\/#\/schema\/person\/d42b18d516a80149d739845749ac6454\"},\"headline\":\"Macquarie Group Ltd (MQG)\",\"datePublished\":\"2020-05-11T03:49:05+00:00\",\"dateModified\":\"2020-05-13T06:18:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/\"},\"wordCount\":893,\"publisher\":{\"@id\":\"https:\/\/thepatientinvestor.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg.png\",\"keywords\":[\"Macquarie Group\",\"MQG\"],\"articleSection\":[\"Australian Growth\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/\",\"url\":\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/\",\"name\":\"Macquarie Group Ltd (MQG) - the patient investor\",\"isPartOf\":{\"@id\":\"https:\/\/thepatientinvestor.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg.png\",\"datePublished\":\"2020-05-11T03:49:05+00:00\",\"dateModified\":\"2020-05-13T06:18:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#primaryimage\",\"url\":\"https:\/\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg.png\",\"contentUrl\":\"https:\/\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/thepatientinvestor.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Macquarie Group Ltd (MQG)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/thepatientinvestor.com\/#website\",\"url\":\"https:\/\/thepatientinvestor.com\/\",\"name\":\"The Patient Investor\",\"description\":\"Smart. Strategic. Unfiltered. \",\"publisher\":{\"@id\":\"https:\/\/thepatientinvestor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/thepatientinvestor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/thepatientinvestor.com\/#organization\",\"name\":\"The Patient Investor Pty Ltd\",\"url\":\"https:\/\/thepatientinvestor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"width\":250,\"height\":250,\"caption\":\"The Patient Investor Pty Ltd\"},\"image\":{\"@id\":\"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/profile.php?id=61572934660810\",\"https:\/\/www.instagram.com\/colin_thepatientinvestor\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/thepatientinvestor.com\/#\/schema\/person\/d42b18d516a80149d739845749ac6454\",\"name\":\"Colin Twiggs\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"caption\":\"Colin Twiggs\"},\"description\":\"Colin Twiggs is a former investment banker with almost 40 years of experience in financial markets. He co-founded Incredible Charts and writes the popular Trading Diary and Patient Investor newsletters. Using a top-down approach, Colin identifies key macro trends in the global economy before evaluating selected opportunities using a combination of fundamental and technical analysis. Focusing on interest rates and financial market liquidity as primary drivers of the economic cycle, he warned of the 2008\/2009 and 2020 bear markets well ahead of actual events. He founded PVT Capital (AFSL No. 546090) in May 2023, which offers investment strategy and advice to wholesale clients.\",\"sameAs\":[\"https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/\",\"https:\/\/www.instagram.com\/colin_thepatientinvestor\",\"https:\/\/au.linkedin.com\/in\/colintwiggs\"],\"url\":\"https:\/\/thepatientinvestor.com\/index.php\/author\/investor\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Macquarie Group Ltd (MQG) - the patient investor","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Macquarie Group Ltd (MQG) - the patient investor","og_description":"Stock: Macquarie Group Ltd Exchange: ASX Symbol: MQG Date: 11-May-20 Latest price: $108.50 Market Cap: $38.8 bn Fair Value: $125.42 Forward P\/E: 15.6 FV Payback (Years): 11 Forward Dividend Yield: 4.09% CET1 Capital Ratio: 12.2% Financial Y\/E: 31-Mar-21 Rating: HOLD Sector: Financial Services Industry: Capital Markets Investment Theme: Dividends &amp; Growth LT Trends: none Summary &hellip; Continue reading \"Macquarie Group Ltd (MQG)\"","og_url":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/","og_site_name":"the patient investor","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61572934660810","article_author":"https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/","article_published_time":"2020-05-11T03:49:05+00:00","article_modified_time":"2020-05-13T06:18:49+00:00","og_image":[{"url":"http:\/\/static.incrediblecharts.com\/images\/2020\/2020-05-11-mqg.png","type":"","width":"","height":""}],"author":"Colin Twiggs","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Colin Twiggs","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#article","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/"},"author":{"name":"Colin Twiggs","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/d42b18d516a80149d739845749ac6454"},"headline":"Macquarie Group Ltd (MQG)","datePublished":"2020-05-11T03:49:05+00:00","dateModified":"2020-05-13T06:18:49+00:00","mainEntityOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/"},"wordCount":893,"publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"image":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg.png","keywords":["Macquarie Group","MQG"],"articleSection":["Australian Growth"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/","url":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/","name":"Macquarie Group Ltd (MQG) - the patient investor","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#primaryimage"},"image":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg.png","datePublished":"2020-05-11T03:49:05+00:00","dateModified":"2020-05-13T06:18:49+00:00","breadcrumb":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#primaryimage","url":"https:\/\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg.png","contentUrl":"https:\/\/www.incrediblecharts.com\/images\/2020\/2020-05-11-mqg.png"},{"@type":"BreadcrumbList","@id":"https:\/\/thepatientinvestor.com\/index.php\/2020\/05\/11\/macquarie-group-ltd-mqg-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thepatientinvestor.com\/"},{"@type":"ListItem","position":2,"name":"Macquarie Group Ltd (MQG)"}]},{"@type":"WebSite","@id":"https:\/\/thepatientinvestor.com\/#website","url":"https:\/\/thepatientinvestor.com\/","name":"The Patient Investor","description":"Smart. Strategic. Unfiltered. ","publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thepatientinvestor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/thepatientinvestor.com\/#organization","name":"The Patient Investor Pty Ltd","url":"https:\/\/thepatientinvestor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","width":250,"height":250,"caption":"The Patient Investor Pty Ltd"},"image":{"@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61572934660810","https:\/\/www.instagram.com\/colin_thepatientinvestor"]},{"@type":"Person","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/d42b18d516a80149d739845749ac6454","name":"Colin Twiggs","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","caption":"Colin Twiggs"},"description":"Colin Twiggs is a former investment banker with almost 40 years of experience in financial markets. He co-founded Incredible Charts and writes the popular Trading Diary and Patient Investor newsletters. Using a top-down approach, Colin identifies key macro trends in the global economy before evaluating selected opportunities using a combination of fundamental and technical analysis. Focusing on interest rates and financial market liquidity as primary drivers of the economic cycle, he warned of the 2008\/2009 and 2020 bear markets well ahead of actual events. He founded PVT Capital (AFSL No. 546090) in May 2023, which offers investment strategy and advice to wholesale clients.","sameAs":["https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/","https:\/\/www.instagram.com\/colin_thepatientinvestor","https:\/\/au.linkedin.com\/in\/colintwiggs"],"url":"https:\/\/thepatientinvestor.com\/index.php\/author\/investor\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p9tQ4n-5kB","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":19514,"url":"https:\/\/thepatientinvestor.com\/index.php\/2019\/12\/02\/macquarie-group-ltd-mqg\/","url_meta":{"origin":20497,"position":0},"title":"Macquarie Group Ltd (MQG)","author":"Colin Twiggs","date":"December 2, 2019","format":false,"excerpt":"Stock: Macquarie Group Ltd Exchange: ASX Symbol: MQG Date: December 2, 2019 Latest price: $138.16 AUD Market Cap: $49.0 billion Fair Value Estimate: $142.11 Forward P\/E: 16.2 Payback Period: 11 years Financial Y\/E: 31 March Recommendation: Buy Sector: Financial Services Industry: Capital Markets Investment Theme: Dividends & Growth Structural Trends:\u2026","rel":"","context":"In &quot;Australian Growth&quot;","block_context":{"text":"Australian Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/asx-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":18504,"url":"https:\/\/thepatientinvestor.com\/index.php\/2019\/07\/08\/macquarie-mqg\/","url_meta":{"origin":20497,"position":1},"title":"Macquarie Group Ltd (MQG)","author":"Colin Twiggs","date":"July 8, 2019","format":false,"excerpt":"Stock: Macquarie Group Ltd Exchange: ASX Symbol: MQG Date: July 7, 2019 Latest price: $129.79 AUD Market Cap: $44.2 billion Fair Value Estimate: $137.20 Forward P\/E: 15.1 Valuation Model: Dividend Growth Financial Y\/E: 31 March Recommendation: Buy Sector: Financial Services Industry: Capital Markets Investment Theme: Dividends & Growth Structural Trends:\u2026","rel":"","context":"In &quot;Australian Growth&quot;","block_context":{"text":"Australian Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/asx-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":16729,"url":"https:\/\/thepatientinvestor.com\/index.php\/2018\/07\/26\/macquarie-group-mqg\/","url_meta":{"origin":20497,"position":2},"title":"Macquarie Group (MQG)","author":"Colin Twiggs","date":"July 26, 2018","format":false,"excerpt":"Stock: Macquarie Group Symbol: MQG Exchange: ASX Financial Year-end: 31 March Latest price: $121.48 Date: July 26, 2018 Company Profile Macquarie Group is Australia's only sizable investment bank. The firm was innovative in setting up large infrastructure funds which provided a captive client for the group but most of these\u2026","rel":"","context":"In &quot;Australian Growth&quot;","block_context":{"text":"Australian Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/asx-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":18869,"url":"https:\/\/thepatientinvestor.com\/index.php\/2019\/09\/16\/australian-growth-performance-at-31-august-2019\/","url_meta":{"origin":20497,"position":3},"title":"Australian Growth: Performance at 31 August 2019","author":"Andy","date":"September 16, 2019","format":false,"excerpt":"Australian Growth portfolio performance since inception on 1 July 2018 is set out below. This is too short a period to give a real indication as to how the portfolio will perform in the long-term: we expect to hold most growth stocks for 5 to 10 years. Performance of Individual\u2026","rel":"","context":"In &quot;Australian Growth Performance&quot;","block_context":{"text":"Australian Growth Performance","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/australian-growth-performance\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2019\/09\/australian-performance-20190831.png?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":16666,"url":"https:\/\/thepatientinvestor.com\/index.php\/2018\/07\/16\/entry-points\/","url_meta":{"origin":20497,"position":4},"title":"Entry Points","author":"Colin Twiggs","date":"July 16, 2018","format":false,"excerpt":"When it comes to timing of entries on individual stocks, I keep an eye on the trend of the market index: either the S&P 500 or the ASX 200 for Australian Growth. Provided the index is in an up-trend, I time entries with 21-day Twiggs Trend Index as in the\u2026","rel":"","context":"In &quot;Investment Strategy&quot;","block_context":{"text":"Investment Strategy","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investing\/investment-strategy-2\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":17458,"url":"https:\/\/thepatientinvestor.com\/index.php\/2019\/02\/26\/australian-growth-portfolio-at-3-july-2018\/","url_meta":{"origin":20497,"position":5},"title":"Australian Growth &#8211; Portfolio at 3 July 2018","author":"Colin Twiggs","date":"February 26, 2019","format":false,"excerpt":"This is a model portfolio of Australian growth stocks selected by me on July 1st, 2018. The selection is based on my investment strategy and is more diverse than the International Growth portfolio, including stocks that generate strong dividend income and cyclical gold and resources stocks. Reasons for this are\u2026","rel":"","context":"In &quot;Australian Growth&quot;","block_context":{"text":"Australian Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/asx-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/20497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/comments?post=20497"}],"version-history":[{"count":6,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/20497\/revisions"}],"predecessor-version":[{"id":20505,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/20497\/revisions\/20505"}],"wp:attachment":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/media?parent=20497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/categories?post=20497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/tags?post=20497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}